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Introduction: Amiodarone infusion has been recommended for life-threatening ventricular
arrhythmias. However its eﬀectiveness in Japanese patients has not yet been determined.
Methods: This was an uncontrolled, open-label trial involving patients with hemodynami-
cally unstable ventricular tachycardia (VT) or ventricular ﬁbrillation (VF). Intravenous
amiodarone was delivered as a 125mg bolus followed by infusion of 50mg/h for 6 hours,
then 25mg/h for 42 hours. The primary endpoint for eﬃcacy was the proportion of patients
free from hemodynamically unstable VT/VF at 48-hour. Secondary endpoints included: event
frequency; proportion of patients event-free, treatment outcome, and safety.
Results: Forty-seven patients were enrolled. Forty-one patients were evaluated for eﬃcacy
and safety parameters were assessed for all 47 patients. The proportion of patients free from
hemodynamically unstable VT/VF was 53.9%; the proportion of patients free from
hemodynamically unstable VT/VF relapse or whose treatment was discontinued was 48.8%.
Eight patients died; all deaths were judged, by the investigator, as being unrelated to
amiodarone. No cases of torsades de pointes were reported.Mild abnormal thyroid function was
noted in one patient. No cases of interstitial lung disease or pulmonary ﬁbrosis were observed.
Conclusion: Amiodarone infusion provides a useful tool in preventing acute relapse of life-
threatening ventricular arrhythmias in Japanese patients.
(J Arrhythmia 2007; 23: 131–139)
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Introduction
Sudden cardiac death is responsible for 30,000
deaths annually in Japan and up to 350,000 deaths
per year in USA.1) Ischemic heart disease accounts
for approximately 30% of these events in Japan but
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in USA it is responsible for more than 80% of such
events.2,3) A variety of conditions such as arrhyth-
mogenic right ventricular dysplasia, heart surgery,
and cardiac sarcoidosis, are among the other causes
of sudden cardiac death.1,4) The initial heart rhythm
is an important factor in determining patient survival
in out-of-hospital circulatory arrest. Failure to con-
trol hemodynamically unstable ventricular tachycar-
dia (VT) or ventricular ﬁbrillation (VF) adversely
aﬀects survival.4–6)
Amiodarone, an agent with broad antiarrhythmic
activity, has produced favourable outcomes in the
treatment of life-threatening relapsing arrhythmias
such as VT and VF.7) Oral amiodarone was approved
for the treatment of heart arrhythmias in Japan in
1992.8,9) The use of oral amiodarone is challenging
in emergency cases, as it may take several days to
reach steady state. Intravenous (iv) amiodarone
infusion is rapidly eﬀective and can be used for
the emergency treatment of life-threatening ventric-
ular arrhythmias; its usefulness in the care of
hospitalized patients has been widely demonstrated
in Europe and USA.9–11) A number of studies have
been conducted in USA, including two double-blind
dose-ranging studies,11,12) and a double-blind com-
parison of amiodarone and bretylium.13) Starting
in 1988, these three double-blind studies were
conducted to determine the eﬃcacy and safety of
amiodarone in patients with life-threatening ventric-
ular arrhythmias refractory to lidocaine and procai-
namide. At a dose of amiodarone 1050mg/day (the
approved dose in the USA), the nonrecurrence rate
of hemodynamically deteriorating VT/VF at in the
three studies was 40%, 41% (after 48 hours), and
53% (after 24 hours), respectively. Adverse reactions
were observed in 433/814 subjects (53%) in the
three studies; the adverse reaction with the highest
incidence rate was decreased blood pressure. Death
occurred in 353/814 subjects (43%); the most
common cause was hemodynamically destabilizing
VT/VF, followed by cardiogenic shock and asystole.
For 34 deaths (4%), a causal relationship with the
drug could not be ruled out. Based on these data, the
drug was approved in USA in 1995 as an orphan
drug for the following indications: initiation of
treatment and prophylaxis of frequently recurring
VF and VT in patients refractory to other therapy.
Intravenous amiodarone can also be used to treat
patients with VT/VF in whom oral amiodarone is
indicated but who are unable to take oral medication.
Randomized, double-blind studies have demon-
strated the survival advantage of amiodarone over
control treatment in the management of ventricular
arrhythmias. The Amiodarone in the Out-of-Hospital
Resuscitation of Refractory Sustained Ventricular
Tachyarrhythmia (ARREST)12) study was a random-
ized, double-blind, placebo-controlled study of intra-
venous amiodarone in patients with out-of-hospital
cardiac arrest. Patients who had cardiac arrest with
VF (or pulseless VT) and who had not been
resuscitated after receiving three or more precordial
shocks were randomly assigned to either intravenous
amiodarone 300mg (246 patients) or placebo (258
patients). There was no signiﬁcant diﬀerence be-
tween the amiodarone and placebo groups in the
duration of the resuscitation attempt (meanstan-
dard deviation; 42 16:4 and 43 16:3 minutes,
respectively), the number of shocks delivered (4 3
and 6 5, respectively), or the proportion of patients
who required additional antiarrhythmic drugs after
the administration of the study drug (66% and 73%,
respectively). Recipients of amiodarone were more
likely to survive hospital admission (44% versus
34% of the placebo group; p = 0.03). A further
double-blind randomized study, Amiodarone versus
Lidocaine in Prehospital Refractory Ventricular
Fibrillation Evaluation (ALIVE),12) compared intra-
venous lidocaine with intravenous amiodarone as an
adjunct to deﬁbrillation in 347 patients with out-of-
hospital cardiac arrest. Patients resistant to three
shocks, intravenous epinephrine, and a further shock
and patients who had recurrent ventricular ﬁbrilla-
tion after initially successful deﬁbrillation were
randomly assigned to intravenous amiodarone or
placebo. Compared with lidocaine, amiodarone led
to substantially higher rates of survival from the
time of cardiac arrest to hospital admission (22.8%
versus 12.0%; p = 0.009). Thus, the usefulness of iv
amiodarone has been demonstrated in both hospi-
talized patients with cardiovascular disease and in
the resuscitation patients brought to the critical care
unit of hospitals.
Based on these results, the Advanced Cardiac Life
Support (ACLS) Guidelines were prepared by the
International Liaison Committee On Resuscitation
(ILCOR) (Europe and USA) recommending iv
amiodarone as ﬁrst-line therapy for cardiopulmonary
resuscitation.14) In Japan, iv amiodarone was only
approved recently, and very few reports of its use in
the Japanese population are available. The present
study was undertaken to evaluate the eﬃcacy and
safety of iv amiodarone infusion in Japanese patients
with recurrent life-threatening ventricular arrhyth-
mias.
Methods
This was an open-label, uncontrolled, multicenter
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study conducted in 39 medical centers in Japan.
Hospitalized patients with at least two episodes of
hemodynamically unstable VT/VF within the 24-
hour period prior to inclusion were treated with iv
amiodarone. Hemodynamically destabilizing VT
was deﬁned as arrhythmia with systolic blood
pressure <80mmHg, or clinical signs and symptoms
of shock requiring non-drug therapy to terminate
the arrhythmia. Institutional review boards at each
participating institution approved the study protocol.
Written informed consent was obtained from each
patient or their next of kin before inclusion in the
trial. The study was performed in accordance with
the Pharmaceutical Aﬀairs Law and the Japanese
Ministerial Ordinance on Standards for Clinical
Studies of Medicines (Good Clinical Practice).
Patients
Hospitalized patients aged 20 years with 2
episodes of hemodynamically destabilizing VT or
VF on the day before informed consent and in whom
treatment with lidocaine, mexiletine, or procaina-
mide was ineﬀective or poorly tolerated within 72
hours before giving consent were included. Exclu-
sion criteria included: drug-induced arrhythmias or
arrhythmias due to hypokalemia (potassium <3:0
mEq/L); acute pulmonary edema or cardiogenic
shock (excluding that resulting from VT or VF);
previous treatment with amiodarone, systolic blood
pressure of <90mmHg (excluding patients currently
experiencing VT or VF); sick sinus syndrome,
symptomatic bradycardia (<50 beats/minute), sino-
atrial block, sinus arrest, or atrioventricular block
(excluding patients with pacemaker); QT prolonga-
tion; torsades de pointes, contraindication to oral
amiodarone, as suggested by the prescribing infor-
mation; any patients judged by the investigator as
unsuitable. There was an extremely small number of
prospective subjects eligible for recruitment within
the duration of the study at the limited number of
medical institutions where emergency treatment
facilities for life-threatening arrhythmias and full-
time physicians specialized in treating arrhythmias
were available. The study was thus limited to 47
patients.
Amiodarone was administered as an initial rapid
infusion of 125mg over 10min followed by con-
tinuous iv infusion of 50mg/h for 6 hours (loading
infusion) and then 25mg/h for a further 42 hours
(maintenance infusion). Amiodarone ampoules were
diluted with 500mL of 5% glucose solution for
infusion. At the discretion of the treating physician,
maintenance amiodarone (25mg/h iv) could be
continued for up to 9 days. If judged necessary, an
additional rapid infusion dose of iv amiodarone
(125mg) was permitted. The maximum permitted
daily amiodarone dose was 1,750mg. Concurrent
use of lidocaine and nifekalant was not allowed
during the ﬁrst 48 hours (evaluation period).
After iv amiodarone, treatment could be switched
to oral amiodarone, according to the judgment of
the treating physician. A ﬁnal follow-up visit was
performed at 1 month, which included 12-lead
electrocardiogram (ECG), physical examination,
chest X-ray, laboratory parameters, and assessment
of the blood concentration of amiodarone. At that
time the physician assessed the control of arrhythmia
as either ‘‘good’’ or ‘‘poor.’’
Given the seriousness of the indication and the
small size of the target population, this study was
designed as an uncontrolled study involving one
subject group in order to accumulate as much eﬃcacy
and safety data on Japanese patients as possible.
Assessment of amiodarone serum concentration
For patients who received amiodarone per proto-
col with no additional doses, serum amiodarone
concentrations were measured at 10 and 30min, and
1, 6, 12, 24, and 48 hours after the start of dosing by
high performance liquid chromatography.15)
Evaluation criteria
The primary endpoint for eﬃcacy was the pro-
portion of patients free from hemodynamically
unstable VT or VF at 48 hours, estimated according
to the Kaplan–Meier method. Secondary endpoints
included: frequency of hemodynamically destabiliz-
ing VT or VF; proportion of patients free from
failure events (including relapse of VT/VF and drug
discontinuation); and treatment outcome based on
physician evaluation at 1 month. Safety was assessed
using laboratory tests, physical examinations, 12-
lead ECG, and chest X-ray. Adverse events were
deﬁned as severe if they resulted in discontinuation
of amiodarone infusion, death or disability of the
patient, or if the events had the potential to cause
death or disability.
Statistical considerations
The Kaplan–Meier method was used to determine
the proportion of patients free from hemodynami-
cally destabilizing VT or VF at 48-hour, in order to
estimate the eﬃcacy based on non-recurrence rate of
VT/VF. Kaplan–Meier plots were also used to show
the changes in the non-recurrence rate of hemody-
namically destabilizing VT/VF within 48 hours.
As so few prospective subjects meeting the
inclusion criteria were recruited in emergency treat-
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ment facilities for life-threatening arrhythmias, it
was assumed that an estimated 48-hour non-recur-
rence rate of 40%, with the 95% conﬁdence interval
(CI) not crossing below 20%, would be suﬃcient to
demonstrate that amiodarone provided a meaningful
clinical beneﬁt. Forty-seven patients were required
to detect the 48-hour event-free survival rate. Patient
backgrounds and other factors that may aﬀect the
results were also analyzed.
Results
From January 16, 2003 to December 16, 2004, 47
patients were enrolled and examined in this study.
Relevant demographic and clinical data are shown in
Table 1. Four patients were found to be ineligible
(inclusion criteria not met), one patient died during
the initial rapid infusion stage, and for one patient it
was not possible to acquire valid data during the ﬁrst
48-hour period of the study. Hence, 41 patients were
evaluated for eﬃcacy; safety was evaluated for all 47
patients. Presenting arrhythmias included VT, VF,
and VT plus VF and all patients had underlying
cardiac disorder (Table 1).
Efﬁcacy
Among the 41 patients analyzed for eﬃcacy, the
proportion of patients free from hemodynamically
unstable VT or VF estimated by the Kaplan–Meier
method was 72.1% at 6-hour after the end of the
rapid infusion (95% CI: 58.0–86.1%), 64.3% at 12-
hour (49.3–79.3%), 56.6% at 24-hour (41.1–72.2%),
and 53.9% at 48-hour (38.2–69.6%) (Figure 1).
Relapse of hemodynamically destabilizing VT/VF
most often occurred during the ﬁrst 24 hours of
treatment. The mean  standard deviation of hemo-
dynamically destabilizing VT/VF throughout the
eﬃcacy evaluation period was 0:36 1:1 episodes/
hour.
All VT/VF episodes and treatment discontinua-
tions were considered as failure events. The propor-
tion of patients remaining event-free was 68.3% at
6-hour (95% CI: 51.9–81.9%), 61.0% at 12-hour
(44.5–75.8%), 51.2% at 24-hour (35.1–67.1%), and
48.8% at 48-hour (32.9–64.9%) (Figure 2).
One patient died during the initial treatment
period and one patient had no eﬃcacy data within
48 hours of initial rapid infusion. These patients
did not receive a 1 month follow up. Arrhythmias
remained well controlled in 82.4% of surviving
patients in the evaluable population, which was
similar to the result in the safety population (83.8%)
(Table 2). Table 3 shows the results of stratiﬁed
Table 1 Patient demographics.
Population
Characteristic
Efﬁcacy Safety
No. of patients 41 47
Sex, n (%)
Male 27 (65.9) 33 (70.2)
Female 14 (34.1) 14 (29.8)
Mean  SD age, years 64:2 14:2 65:4 14:2
Mean  SD weight, kg 57:6 9:8 58:8 11:7
Presenting arrhythmia, n(%)
VT 23 (56.1) 25 (53.2)
VF 9 (22.0) 10 (21.3)
VT and VF 9 (22.0) 12 (25.5)
Cardiac disease, n (%)
Coronary artery disease 23 (56.1) 27 (57.5)
Cardiomyopathy 6 (14.6) 6 (12.8)
Valvular disease 13 (31.7) 16 (34.0)
NYHA functional class, n (%)
I/II 22 (53.7) 26 (55.3)
III 5 (12.2) 6 (12.8)
IV 7 (17.1) 8 (17.0)
Unknown 7 (17.1) 7 (14.9)
LVEF
Mean  SD, % 39:1 20:3 38:5 19:3
30%, n (%) 21 (51.2) 25 (53.2)
<30%, n (%) 16 (39.0) 18 (38.3)
A patient could have more than one cardiac disease.
LVEF, left ventricular ejection fraction; NYHA, New
York Heart Association; SD, standard deviation; VF,
ventricular ﬁbrillation; VT, hemodynamically destabiliz-
ing ventricular tachycardia.
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analysis of the proportion of patients free from
hemodynamically destabilizing VT or VF. This
proportion was higher for patients with LVEF
30% than for patients with LVEF <30%. The
proportion of female patients (2 of 14) who suﬀered
relapse of VT/VF was higher than in males.
However, when cardiac function was analyzed
separately in males and females, only 11 of the 27
men (40.7%) had favorable cardiac function com-
pared with 10 of the 14 women (71.4%).
Safety
All patients had at least one adverse event related
to their underlying cardiac condition. During the
48-hour loading and maintenance period, treatment
was discontinued by the investigator in 4 patients
due to adverse events. These four events were: QTc
prolongation (n ¼ 2), fall in blood pressure (n ¼ 1),
and low cardiac output syndrome (n ¼ 1).
During the 1-month follow-up period, 7 of the 41
patients (17.1%) included in the eﬃcacy evaluation
and 8 of the 47 (17.0%) patients included in the
safety evaluation died while 7 patients (14.9%)
enrolled in the study developed severe adverse
events for which a causal relationship with the
investigational product could not be ruled out
(Table 4). The eight deaths were due to VT/VF
(n ¼ 3), sepsis (n ¼ 2), cardiogenic shock (n ¼ 1),
myocardial rupture (n ¼ 1), and respiratory failure
(n ¼ 1). The majority of deaths were due to under-
lying cardiac disease. In the two cases of sepsis, both
patients had been hospitalized for infection before
study entry. Among the 7 patients with severe
adverse events, 6 experienced severe cardiovascular
adverse reactions, including prolongation of QTc
interval, bradycardia, VT/VF, hypotension, and low
cardiac output syndrome. The seventh patient expe-
rienced a severe non-cardiovascular adverse reac-
tion: liver function disorder (elevated serum trans-
aminase twice the upper limit of normal). In this
patient, almost 1 month after the study infusion was
stopped, glutamyl oxaloacetic transaminase increas-
ed to 1400 units and glutamyl pyruvic transaminase
had increased to 715 units. Hepatic enzymes slowly
returned to normal over 3 weeks.
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Figure 2 Proportion of failure event-free patients (%).
Failure events includes all the VT/VF-relapse and discontinuation
of the treatment.
Table 2 Patient outcomes.
Population
Efﬁcacy Safety
Outcome at 1 month follow-up, n (%) 45
Dead 7 (17.1) 8 (17.8)
Alive 34 (82.9) 37 (82.2)
Control of arrhythmia in surviving patients, n (%)
Good 28 (82.4) 31 (83.8)
Poor 6 (17.6) 6 (16.2)
Table 3 Stratiﬁed analysis of the proportions of VT/VF-
free cases.
Parameter Category n
No. of
patients
with
VT/VF
Patients
without
VT/VF
(95% CI)
(%)
Total 41 18 53.9 (38.2–69.6)
Gender Male 27 16 40.7 (22.2–59.3)
Female 14 2 83.3 (62.2–100.0)
Age <70 years 25 11 54.7 (34.9–74.6)
70 years 16 7 53.3 (28.1–78.6)
AMI Present 11 5 51.9 (21.2–82.7)
Absent 30 3 55.2 (37.1–73.3)
Diagnosis VT 23 12 47.8 (27.4–68.2)
VT/VF
and VF
18 6 63.0 (39.5–86.6)
NYHA
classiﬁcation I/II 22 9 58.7 (38.0–79.5)
III/IV 12 6 40.4 (9.9–70.9)
LVEF <30% 16 8 43.3 (17.4–69.3)
30% 21 7 66.7 (46.5–86.8)
Proportion (95% CI) was calculated using Kaplan–Meier
method (Greenwood formula). AMI, acute myocardial
infarction; CI, conﬁdence interval; LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association;
VF, ventricular ﬁbrillation; VT, hemodynamically desta-
bilizing ventricular tachycardia.
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Interstitial lung disease, pulmonary ﬁbrosis, and
corneal pigmentation—known adverse reactions with
oral amiodarone treatment—were not reported in this
study. One case of mild hypothyroidism, as deﬁned
by the investigator, was seen. Neither torsades de
pointes nor bundle-branch block were observed.
Thirty-six and 17 of 47 subjects showed abnor-
malities in QRS and QT, respectively. A mild QTc
prolongation was seen in 8 (30–60ms) and in 19
(>60ms) of 47 subjects.
Serum amiodarone levels
Figure 3 shows the serum amiodarone concentra-
tions for the 5 patients who did not receive any
additional doses of amiodarone that were allowed by
the protocol. They received the initial rapid, loading,
and maintenance infusions. In these cases, serum
amiodarone levels rose quickly after the start of the
rapid infusion and remained within the eﬀective
range (1.0–2.5 mg/mL) from 30min to 48-hour after
the start of dosing. The remaining patients were
given doses of other antiarrhythmic agents or addi-
tional doses of amiodarone at the discretion of the
investigator. These patients were thus excluded from
the analysis of serum amiodarone levels in this
report.
Discussion
Amiodarone injection is the only antiarrhythmic
drug whose eﬃcacy against life-threatening arrhyth-
mias has been demonstrated in prospective, random-
ized, double-blind studies at critical care units.12,13)
However its eﬀectiveness as an iv therapy has not
previously been examined in Japanese patients. In
the present study, 39 of the 41 patients included in
the eﬃcacy evaluation had not responded to previous
treatment with lidocaine or mexiletine, and 4 of
these 41 patients had not responded to procainamide.
Thirteen of the 41 patients were switched from
nifekalant therapy to amiodarone because the former
treatment did not provide adequate relapse preven-
tion. Amiodarone was eﬀective in preventing relapse
of VT/VF in 5 of these 13 patients.
The results of this study conﬁrm that iv amiodar-
one is eﬀective for the prevention of hemodynami-
cally destabilizing VT or VF in Japanese patients.
The proportion of patients free from hemodynami-
cally destabilizing VT or VF 6 hours after the end of
the rapid infusion was 72.1% and at 48-hour 53.9%
of patients were still relapse free. Relapse of VT/VF
most often occurred during the ﬁrst 24 hours of
treatment. Severe adverse reactions to amiodarone
were seen with the iv route in 8 of the 47 patients,
but these were adequately dealt with using clinical
measures. Although 8 patients died during the
follow-up period, these deaths were associated with
the severity of the underlying disease and were not
attributed to amiodarone. Given the severity of the
patients’ conditions and the urgent need for treat-
ment, the safety of amiodarone can be considered as
acceptable.
The dose levels of amiodarone used in this study
were based on data from a dose-determination study
conducted in USA after taking into account the
diﬀerence in body weight between Americans and
Table 4 Severe adverse reactions (adverse events whose
causal relationship to the investigational drug could not be
ruled out).
Event Number of patients (%)(n ¼ 47)
All cardiovascular 6 (12.8)
Hypotension 1 (2.1)
Bradycardia 2 (4.3)
Increase of QTc interval 2 (4.3)
Low cardiac output syndrome 1 (2.1)
Ventricular tachycardia 2 (4.3)
Ventricular ﬁbrillation 1 (2.1)
Non-cardiovascular 1 (2.1)
Liver dysfunction 1 (2.1)
Some patients may have had more than one concurrent
event.
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Japanese.16–18) The present study in Japanese patients
demonstrated that a rapid infusion of amiodarone
resulted in a quick increase in serum amiodarone
levels, which then remained within the therapeuti-
cally eﬀective range by means of maintenance
infusions.
The proportion of patients free from hemodynami-
cally destabilizing VT or VF during the 48-hour
observation period and the proportion of patients free
from all failure events during the same period were
compatible with those reported by investigators
outside of Japan.16–18) Amiodarone administered
via the iv route is thus eﬀective in preventing
recurrence of VT or VF.
The stratiﬁed analysis in Table 3 revealed a diﬀer-
ence in the proportion of VT/VF-free cases between
males and females, but this diﬀerence seems to be
attributable to the small sample size rather than to a
marked gender-related diﬀerence in cardiac func-
tion. It therefore seems reasonable to suggest that iv
amiodarone is equally eﬃcacious in both men and
women.
Until recently, the only available agents in Japan
for the treatment of life-threatening ventricular
arrhythmias were lidocaine, procainamide, mexile-
tine, and nifekalant. Reports on the utility of
lidocaine are sparse and some investigators suggest
that lidocaine elevates the threshold for deﬁbrilla-
tion.19) Procainamide is sometimes used in lidocaine-
resistant cases, but it is likely to decrease blood
pressure. The prominence of both lidocaine and
procainamide in cardiopulmonary resuscitation
guidelines has been decreasing in recent years.20)
Nifekalant is a Class III antiarrhythmic agent that
has been developed and approved for clinical use in
Japan. It is considered to lower the threshold for VF
and has little eﬀect or only a mild positive inotropic
eﬀect on myocardial contractility. In a retrospective
study of 120 patients with cardiac arrest with VF that
persisted after 3 shocks from an external deﬁbrilla-
tor, lidocaine and nifekalant were compared for
short-term survival. Nifekalant was associated with
signiﬁcantly higher rates of survival after hospital
admission (67% versus 37%, p < 0:001) and 24-
hour survival (53% versus 31%, p ¼ 0:01).21) There
were some limitations to this study: it was retro-
spective and was not designed as a controlled
clinical trial, because patients who had previously
received lidocaine served as control. The baseline
clinical characteristics showed a lower dose of
epinephrine was used in the nifekalant group than
for the controls.
Lidocaine and nifekalant were used during diﬀer-
ent periods and thus the outcomes may have been
aﬀected by factors such as technical advances and
improved medical care.
There is little evidence of the eﬃcacy of nifeka-
lant in the management of cardiac arrest. In a study
of 91 cases of VT/VF resistant to a single dose of
lidocaine followed by DC shock, patients were
divided into two groups. In the ﬁrst group, nifekalant
was used (0.15–0.3mg/kg) and DC shocks were
administered. In the second group, additional lido-
caine was given up to a maximum of 3mg/kg in
combination with DC shock. Sinus rhythm was
restored in 43% of the non-nifekalant group and in
81% of the nifekalant group. The deﬁbrillation rate
was higher in the nifekalant group than for lidocaine
alone and the VT/VF rate reduction eﬀect could be
maintained even with acidosis. However, sinus
bradycardia, and torsades de pointes were occasion-
ally observed with nifekalant therapy.22)
Regarding safety parameters, all of the 47 patients
developed at least one treatment-emergent adverse
event and 8 patients died during the 1-month follow-
up period. Causal relationship to the drug was ruled
out for all cases of death. Severe adverse events were
noted in 18 patients for whom a relationship to
amiodarone could not be excluded in 7 patients.
Severe adverse reactions include cardiac disorders
(6 patients), laboratory ﬁnding abnormalities (2
patients), and an administration to hospital (1
patient). All of the adverse reactions observed in this
study have been previously described with oral
amiodarone in Japan and iv amiodarone in other
countries. Interstitial pulmonary diseases, a known
adverse event with long-term oral amiodarone
therapy, were not reported in the present study. QTc
interval was prolonged in 27 patients but torsades de
pointes was not observed and no bundle-branch
block was recorded. An increase in QT interval is
linked to the pharmacologic eﬀect of amiodarone.
The purpose of this study was to evaluate the
eﬃcacy of amiodarone for the management of VT/
VF. We did not use a control arm, as amiodarone iv
is indicated for severely ill patients who require
urgent treatment. We demonstrated the eﬀectiveness
of amiodarone as 53.9% of patients were free of
recurrence at 48-hour. Eﬃcacy of amiodarone in
terms of the proportion of patients free from VT or
VF and the proportion of failure-free cases in this
study was comparable with or higher than that of
both the amiodarone group and placebo groups as
reported in studies conducted in Europe and USA,
and the safety of the drug was within an acceptable
range. The results of this study demonstrate the great
utility of amiodarone via the iv route as a means of
preventing life-threatening ventricular arrhythmias
Katoh T Eﬃcacy and safety of intravenous amiodarone infusion
137
in Japanese patients. Limitations of the present study
were a protocol which did not include a control and
the small number of patients enrolled in the study.
Therefore we must exercise care in interpreting the
results of this study.
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